₹358.6▲2.27%
Overview of Shilpa Medicare Ltd
Shilpa Medicare Ltd has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, for Betahistine Dihydrochloride Orodispersible Films. The company also successfully completed an inspection by Japan’s Pharmaceuticals and Medical Devices Agency. Shilpa is the first company to receive approval for the 24 mg strength as a film formulation in the UK.
Shilpa Medicare Receives Approval for Pemetrexed Injections - 01 Aug, 2023
Shilpa Medicare Limited has received approval from CDSCO to manufacture and sell Pemetrexed Ready to Use injections in India under the brand name VRTU.
Shilpa Medicare's Balance Sheet Poses Risk to Business - 17 Jul, 2023
Shilpa Medicare Ltd has a net debt of about ₹7.74b, with liabilities totaling ₹7.75b more than its cash and short-term receivables. Shareholders face high net debt to EBITDA ratio (7.6) and weak interest coverage, making the debt burden substantial.
Shilpa Medicare Stock Surges on Positive News - 30 Jun, 2023
Shilpa Medicare Ltd's stock jumps 15.7% on high volumes as HNIs buy shares and anticipate a corporate development. Additionally, the company's subsidiary, Shilpa Biologicals, received marketing authorization for its Adalimumab injection.
Shilpa Medicare Ltd board to evaluate rights issue proposal - 21 Jun, 2023
Pharmaceutical company Shilpa Medicare is considering a rights issue of equity shares. The US FDA classified its Hyderabad unit as Voluntary Action Indicated (VAI) in late May, which is a relief for the company at a time when scrutiny from the US drug regulator is leading to delays in key launches for several pharmaceutical companies.
Shilpa Medicare Ltd stock jumps 13.56% amid heavy volumes - 20 Jun, 2023
Shares of Shilpa Medicare Ltd surged by 13.56% to hit a day high of Rs 272.95 over its previous close of Rs 240.35 amid heavy volumes. The company reported a net loss of Rs 8 crore in Q4 FY23, compared to a net profit of Rs 29.50 crore during the same period last year due to tax outflow. However, the stock has an average target price of Rs 292, suggesting a potential upside of 9.67%. Support on the counter could be seen at Rs 255.
2.22%
Downside
Day's Volatility:4.95%
Upside
2.73%
37.93%
Downside
52 Weeks Volatility:47.17%
Upside
9.24%
Returns % | |
1 Month Return | -3.67 % |
3 Month Return | 23.36 % |
1 Year Return | -3.69 % |
Market Stats | |
Previous Close | ₹350.65 |
Open | ₹352.70 |
Volume | 3.11L |
Market Cap | ₹3,043.71Cr |
Organisation | Shilpa Medicare Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Fundamentals of Shilpa Medicare Ltd
Retail Investor have increased holdings from 35.71% to 39.37% in Jun 2023 quarter
Revenue is up for the last 2 quarters, 265.56 Cr → 265.73 Cr (in ₹), with an average increase of 0.1% per quarter
In the last 1 year, Dr Reddys Laboratories Ltd has given 24.5% return, outperforming this stock by 28.2%
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 123.7% return, outperforming this stock by 161.6%
Promoters holdings remained unchanged at 50.01% of holdings in Jun 2023 quarter
Foreign Institutions have decreased holdings from 13.74% to 10.26% in Jun 2023 quarter
Netprofit is down for the last 2 quarters, -6.62 Cr → -8.04 Cr (in ₹), with an average decrease of 21.5% per quarter
In the last 3 years, SHILPAMED stock has moved down by -37.9%
Shilpa Medicare Ltd in the last 5 years
Lowest (-100.97x)
September 7, 2023
Today (-94.77x)
September 28, 2023
Industry (47.79x)
September 28, 2023
Highest (503.73x)
February 21, 2023
Funds | Holdings |
![]() | 0.37% |
Investors | Holdings % | Prev. 2 periods | 3M change |
---|---|---|---|
Promoter Holdings | 50.01% | 0.00 | |
Foreign Institutions | 10.26% | ||
Mutual Funds | 0% | ||
Retail Investors | 39.37% | 10.25 | |
Others | 0.36% |
Technicals of Shilpa Medicare Ltd share
News & Events of Shilpa Medicare Ltd
Why did Shilpa Medicare share price rose 10% on Tuesday (11th April 2023)?
Shilpa Medicare share price jumped around 10% as the company received approval from the US drug regulator for its psoriatic arthritis drug to be sold in US.
66.44% of INDmoney users answered correctly
Shilpa Medicare Ltd(SHILPAMED | Price |
---|---|
52 Week High | ₹391.75 |
52 Week Low | ₹222.6 |
Shilpa Medicare Ltd(SHILPAMED | Returns |
---|---|
1 Day Returns | 7.95% |
1 Month Returns | -3.67% |
3 Month Returns | 23.36% |
1 Year Returns | -3.69% |